951 results on '"de Boeck, K"'
Search Results
2. ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals
3. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria
4. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders’ consensus view
5. Building global development strategies for cf therapeutics during a transitional cftr modulator era
6. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis
7. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
8. Real life practice of sweat testing in Europe
9. Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
10. WS09.02 Theratyping molecular defects of CFTR rare variants in patient derived rectal organoids
11. P071 Evaluation of CFTR modulator efficacy by rectal organoid morphology analysis (ROMA) indexes
12. WS04.06 Validation of rectal organoid morphology analysis (ROMA) as a novel physiological CFTR assay for diagnosis of cystic fibrosis
13. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial
14. Year to year change in FEV1 in patients with cystic fibrosis and different mutation classes
15. Biological variability of the sweat chloride in diagnostic sweat tests: A retrospective analysis
16. Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations
17. AB0651 INDIRECT HEALTH RELATED COST IN pSS PATIENTS IN RELATION TO SYMPTOM BASED ENDOTYPES
18. POS0817 THE ROLE OF IGG N-LINKED SIALYLATION AND GALACTOSYLATION IN PRIMARY SJÖGREN’S SYNDROME IN ITS POTENTIAL AS A MARKER OF DISEASE STATE AND DISEASE ACTIVITY
19. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis
20. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study
21. 692 Importance of cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid testing to uncover other variants in cystic fibrosis genotype that affect cystic fibrosis transmembrane conductance regulator expression
22. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis
23. Lung clearance index: Evidence for use in clinical trials in cystic fibrosis
24. WS06.01 HIT-CF organoid screen with ELX-02 for people with CFTR nonsense mutations as a predictive tool for clinical response
25. P025 Assessment of CFTR modulator combinations in rectal organoids from F508del homozygous patients with cystic fibrosis
26. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis
27. POS0742 DISCRIMINATIVE POWER OF SALIVARY GLAND ULTRASOUND IN RELATION TO ENDOTYPES IN SUSPECTED AND DEFINITE PRIMARY SJÖGREN’S SYNDROME
28. Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society–Clinical Trials Network (ECFS-CTN)
29. New clinical diagnostic procedures for cystic fibrosis in Europe
30. Recommendations for the classification of diseases as CFTR-related disorders
31. Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials
32. Pulmonary Status During Childhood After Corrected Congenital Esophageal Atresia
33. Nouvelles techniques d'évaluation dans la mucoviscidose
34. 660: Screening of ELX-02 readthrough effect by forskolin-induced swelling assay in CFTR nonsense mutation–bearing organoids as predictive test for clinical trial patient stratification
35. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
36. Value of allohaemagglutinins in the diagnosis of a polysaccharide antibody deficiency
37. Expression of soluble triggering receptor expressed on myeloid cells-1 in childhood CF and non-CF bronchiectasis
38. Early referral to cystic fibrosis specialist centre impacts on respiratory outcome
39. Pulmonary alveolar microlithiasis: a case report and review of the literature
40. Fabry disease in a patient with Turner syndrome
41. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
42. Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF alpha monoclonal antibodies
43. P031 The last 10%: small molecule screening for correctors of rare CFTRprocessing mutations
44. WS09.2 Elexacaftor combinations (partially) restore CFTR function to previously drug-refractory mutations G85E and N1303K
45. P023 Characterisation of CFTR function in a patient with the F508del/ CFTRdup1–3 genotype
46. Pediatric emergencies: thoracic emergencies
47. Hemoptysis after orthopedic surgery in an adolescent boy
48. EFFICACY AND SAFETY BY AGE GROUP FROM THE PHASE III STUDIES OF BRONCHITOL (INHALED MANNITOL) IN PATIENTS WITH CF: 236
49. MODIFIED NASAL CATHETER FOR MEASUREMENT OF NASAL POTENTIAL DIFFERENCE IMPROVES REPRODUCIBILITY: 218
50. WS11.3 The last 10%: small molecule screening for correctors of rare CFTR processing mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.